

# **The Correlation Between Fetal Hemoglobin in Maternal Blood and The Severity of Pre-eclampsia**

## **Thesis**

Submitted for Partial Fulfillment of Master Degree  
in **Obstetrics & Gynecology**

**By**

**Mariam Mohsen Ahmed Nassar**  
M.B.B.Ch – Ain Shams University 2009  
Resident of Obstetrics & Gynecology  
Ain Shams University Maternity Hospital

**Under Supervision of**

**Prof. Magdy Hassan Kolaib**

Professor of Obstetrics and Gynecology  
Faculty of Medicine – Ain Shams University

**Dr. Mohamed Mahmoud Abdel Aleem**

Lecturer of Obstetrics and Gynecology  
Faculty of Medicine – Ain Shams University

**Dr. Botheina Ahmed Thabet Farweez**

Lecturer of Clinical Pathology  
Faculty of Medicine – Ain Shams University

**Faculty of Medicine**  
**Ain Shams University**

2015

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

وَقَدْ اَعْمَلُوا فَسَيَرَى اللَّهُ عَمَلَكُمْ  
وَرَسُولُهُ وَالْمُؤْمِنُونَ

صدق الله العظيم

سورة التوبة آية (١٠٥)



## Acknowledgement

*First, thanks are all due to **Allah** for Blessing this work until it has reached its end, as a part of his generous help throughout our life.*

*I would first like to express my unlimited gratitude to **Prof. MagdyHassan Kolaib**, Professor of Obstetrics and Gynecology, Faculty of Medicine – Ain Shams University, for his acceptance to supervise my work, for his continuous support and his valuable advices. Without his encouragement and help I would not have been able to finish this work,*

*Also, I would like to express my sincere and deep gratitude to **Dr. Mohamed Mahmoud Abdel Aleem**, Lecturer of Obstetrics and Gynecology, Faculty of Medicine – Ain Shams University for his help, cooperation and valuable suggestions. It is a great honor to work under his guidance and supervision.*

*And I would like to express my thanks and appreciation to **Dr. Botheina Ahmed Thabet Farweez**, Lecturer of Clinical Pathology, Faculty of Medicine – Ain Shams University for her valuable help and keen interest in the progress and accomplishment of this work, her guidance, cooperation and helpful instructions.*

*I am extremely sincere to **my family** who stood beside me throughout this work giving me their support.*

---



*Mariam Mohsen Ahmed Nassar*

# List of Contents

	Page
List of abbreviations.....	i
List of Figures .....	iii
List of Tables .....	v
Protocol .....	--
<b>Introduction</b> .....	1
<b>Aim of Work</b> .....	5
<b>Review of Literature</b> .....	6
<b>Chapter (1): Pre-eclampsia</b> .....	6
<b>Chapter (2): Fetal Hemoglobin</b> .....	37
<b>Chapter (3): Fetal Hemoglobin and Pre-eclampsia...</b>	47
<b>Patients and Methods</b> .....	54
<b>Results</b> .....	64
<b>Discussion</b> .....	76
<b>Summary</b> .....	82
<b>Conclusion</b> .....	88
<b>Recommendations</b> .....	89
<b>References</b> .....	90
<b>Arabic Summary</b> .....	-

## List of Abbreviations

<b>ACOG</b>	: American college of obstetrics and gynaecology.
<b>AFLP</b>	: Acute fatty liver of pregnancy
<b>ALT</b>	: Alanine aminotransferase
<b>AST</b>	: Aspartate aminotransferase
<b>AUC</b>	: Area under the curve
<b>BMI</b>	: Body mass index
<b>BP</b>	: Blood pressure
<b>BPP</b>	: Biophysical profile
<b>CBC</b>	: Complete blood count
<b>CI</b>	: Confidence interval
<b>CNS</b>	: Central nervous system
<b>CO<sub>2</sub></b>	: Carbon dioxide
<b>DA</b>	: Diagnostic accuracy
<b>DBP</b>	: Diastolic blood pressure
<b>DIC</b>	: Disseminated intravascular coagulopathy
<b>DNA</b>	: Deoxyribonucleic acid
<b>ELISA</b>	: Enzyme-linked immunosorbant assay
<b>ET</b>	: Endothelin
<b>Fe</b>	: Iron
<b>GA</b>	: Gestational age
<b>Hb</b>	: Hemoglobin
<b>Hb F</b>	: Fetal hemoglobin
<b>HPFH</b>	: Hereditary persistence of fetal hemoglobin
<b>HRP</b>	: Horseradish Peroxidase
<b>HUS</b>	: Hemolytic uremic syndrome
<b>INR</b>	: International normalised ratio
<b>IQR</b>	: Inter-quartile range
<b>ISSHP</b>	: International Society of the Study of Hypertension in Pregnancy
<b>IU</b>	: International unit
<b>IUGR</b>	: Intrauterine growth restriction
<b>KIRs</b>	: Killer immunoglobulin receptors
<b>LDH</b>	: Lactate dehydrogenase
<b>MAP</b>	: Mean arterial pressure
<b>NADH</b>	: Nicotinamide adenine dinucleotide hydrogen
<b>NADPH</b>	: Nicotinamide adenine dinucleotide phosphate

## **List of Abbreviations (Cont.)**

<b>NHBPEP:</b>	The National High Blood Pressure Education Program
<b>NICE</b>	: National Institute for Health and Care Excellence
<b>NK</b>	: Natural killer
<b>NO</b>	: Nitric oxide
<b>NST</b>	: Nonstress test
<b>O<sub>2</sub></b>	: Oxygen
<b>PIGF</b>	: Placental growth factor
<b>PNV</b>	: Predictive negative value
<b>PPV</b>	: Predictive positive value
<b>PT</b>	: Prothrombin time
<b>RBC</b>	: Red blood cell
<b>RIA</b>	: Radioimmunoassay
<b>RO</b>	: Reactive oxygen species
<b>ROC</b>	: Receiver operator characteristics
<b>r<sub>s</sub></b>	: Spearman's rank correlation coefficient
<b>SBP</b>	: Systolic blood pressure
<b>SD</b>	: Standard deviation
<b>SE</b>	: Standard error
<b>SGOT</b>	: Serum glutamic oxaloacetic transaminase
<b>SGPT</b>	: Serum glutamic pyruvic transaminase
<b>SLE</b>	: Systemic lupus erythematosus
<b>SOD</b>	: Superoxide dismutase
<b>SPSS</b>	: Statistical package for social sciences
<b>TTP</b>	: Thrombotic thrombocytopenic purpura
<b>VEGF</b>	: Vascular endothelial growth factor

## List of Figures

<b>Fig.</b>	<b>Title</b>	<b>Page</b>
(1)	The main endocrine systems identified in pre-eclampsia.	10
(2)	Hemoglobin structure	40
(3)	Comparison between adult and fetal hemoblobin .	45
(4)	Informed written consent.	59
(5)	Severity of pre-eclampsia among the pre-eclampsia group.	65
(6)	Comparison between control and case groups regarding blood pressure.	68
(7)	Comparison between mild and severe pre-eclampsia groups regarding blood pressure.	68
(8)	Comparison between control and case groups regarding urine albumin.	69
(9)	Comparison between mild and severe pre-eclampsia groups regarding urine albumin.	69
(10)	Comparison between study groups regarding Hemoglobin F.	71
(11)	Comparison between mild and severe pre-eclampsia groups regarding Hemoglobin F.	71

## List of Figures (Cont.)

<b>Fig.</b>	<b>Title</b>	<b>Page</b>
(12)	Correlation between Hemoglobin F and SBP.	73
(13)	Correlation between Hemoglobin F and urine albumin.	73
(14)	ROC curve for HbF, SBP and urine albumin in diagnosis of pre-eclampsia patients from control patients.	74



## List of Tables

Table	Title	Page
(1)	Severity of pre-eclampsia among the pre-eclampsia group.	65
(2)	Comparison between study groups regarding demographic data (age, gestational age and parity).	66
(3)	Comparison between study groups regarding parameters of diagnosis (blood pressure and urine albumin).	67
(4)	Comparison between study groups regarding Hemoglobin F (ng/ml).	70
(5)	Correlation between Hemoglobin F and age, parity, GA, SBP, DBP and urine albumin among case and control groups.	72
(6)	Performance of HbF, SBP and urine albumin in diagnosis of pre-eclampsia patients from control patients.	74
(7)	Diagnostic characteristics of HbF, SBP and urine albumin in diagnosis of pre-eclampsia patients from control patients	75

# **The Correlation Between Fetal Hemoglobin in Maternal Blood and The Severity of Pre-eclampsia**

*Protocol of thesis*

Submitted for Partial Fulfillment of Master Degree  
in Obstetrics & Gynecology

*By*

**Mariam Mohsen Ahmed Nassar**

M.B.B.Ch – Ain Shams University 2009  
Resident of Obstetrics & Gynecology  
Ain Shams University Maternity Hospital

*Under Supervision of*

**Prof. Magdy Hassan Kolaib**

Professor of Obstetrics and Gynecology  
Faculty of Medicine – Ain Shams University

**Dr. Mohamed Mahmoud Abdel Aleem**

Lecturer of Obstetrics and Gynecology  
Faculty of Medicine – Ain Shams University

**Dr. Botheina Ahmed Thabet Farweez**

Lecturer of Clinical Pathology  
Faculty of Medicine – Ain Shams University

*Faculty of Medicine  
Ain Shams University*

**2014**

# **Introduction**

Pre-eclampsia has been diagnosed in nearly 3 to 7% of pregnant women annually. It has been estimated that each year it affects 8.5 million pregnant women around the world. Pre-eclampsia is responsible for approximately 40% of severe obstetric morbidity and is considered as one of the leading causes of mortality during pregnancy in both mothers and fetuses. The worldwide annual cost is around 18-22 billion US dollars (*Hansson et al., 2013*).

According to the International Society for the Study of Hypertension in Pregnancy (ISSHP), pre-eclampsia can be defined as newly developed hypertension occurring after 20 weeks of pregnancy together with proteinuria. Hypertension involves a systolic blood pressure of more than or equal to 140mmHg and/or a diastolic blood pressure more than or equal to 90 mmHg. There should be two readings with an interval of at least four hours in between. Proteinuria mean total protein in 24 hours equal to or more than 300 mg per day (*Anderson et al., 2011*).

In order to find a definitive treatment for pre-eclampsia we must first understand its pathology. Many theories have been proposed for its pathogenesis and hence pre-eclampsia has been called the 'disease of theories' (*Pepple et al., 2006*).

The fact that termination of pregnancy and delivery of the placenta is necessary in the management of pre-eclampsia

leads to the presumption that the placenta is the source of the pathogenesis. A recent theory composed of two stages is now generally accepted. The first stage begins with a defect in placental formation impairing placental perfusion and oxygen transport which results in ischemia and the formation of free oxygen radicals. High levels of free oxygen radicals lead to oxidative stress causing damage to the placental barrier. This damage causes leakage between the maternal and fetal circulation systems and hence placental and fetal factors leak into the maternal circulation (*Roberts et al., 2009*).

In the second stage, this leakage leads to maternal systemic inflammation and endothelial damage. The leaking fetal and placental factors are usually foreign to the maternal immune system, contributing to the inflammation that aggravates the endothelial damage. Endothelial damage is responsible for the clinical manifestations of preeclampsia: hypertension, edema and proteinuria. The leaking factors link the two stages and identifying them will significantly help in the management of pre-eclampsia (*Tjoa et al., 2006*).

One of these factors is recently thought to be hemoglobin F. Normally it comprises less than 1% of the hemoglobin in adults. Hemoglobin is the major oxygen carrier of blood but it consists of a dangerous component. Hemoglobin is a tetramer consisting of four globin subunits each carrying an iron-containing heme group in its active center. Fetal hemoglobin (Hemoglobin F) is made up by two alpha chains and two gamma chains. Most hemoglobin is

found strictly compartmentalized within erythrocytes, but during pathological hemolytic conditions, quantities of hemoglobin leak out into the circulation (*Sverrisson et al., 2013*).

Increased serum levels of hemoglobin F in maternal blood of pre-eclamptic patients, suggests that free hemoglobin F leaks through the placental barrier and into the maternal circulation. The heme group contains an iron atom whose redox activity is the basis for the strong oxidative reactivity of free hemoglobin which damages lipids, protein and DNA through direct oxidation and generation of free oxygen radicals such as superoxide anions. Free ferrous hemoglobin is a strong binder of the vasodilator nitric oxide which indirectly leads to a vasoconstrictive effect. As a result hemoglobin and its degradation products are toxic and cause oxidative stress, hemolysis, vasoconstriction, kidney and vascular endothelial damage. (*Buehler et al., 2010*)

Once elevated gene-expression levels of hemoglobin F in the lumen of the vessels of pre-eclamptic placentas were found, the hypothesis that hemoglobin F is involved in the cause of pre-eclampsia could be formed. By aggravating the oxidative stress, causing damage to the placental barrier and leaking into the maternal bloodstream causing endothelial damage and vasoconstriction hemoglobin F acts as a potential causative factor of pre-eclampsia (*Hansson et al., 2013*).

Accordingly, hemoglobin F can be used as a prognostic tool for pre-eclampsia. In addition to using it as a diagnostic tool; knowing the factors causing pre-eclampsia will help in its future management. In the case of hemoglobin F, the protein:  $\alpha$ 1-microglobulin has recently been shown to be involved in the defense against cell-free hemoglobin and heme. It is a radical scavenger that has reductase and antioxidant properties. What gives it more privilege to other antioxidants, is that in addition to its antioxidant properties it has the ability to bind to heme groups and has a higher molar capacity and effective clearance mechanisms (*Olsson et al., 2009*).

# Aim of the Work

## **Study Hypothesis:**

The levels of hemoglobin F in maternal blood are correlated to the severity of pre-eclampsia.

## **Study Question:**

Is the level of hemoglobin F in maternal blood correlated to the severity of pre-eclampsia?

This study aims to find a correlation between fetal hemoglobin in maternal blood and the severity of pre-eclampsia, hence if it is proved to be affected by the severity of pre-eclampsia, factors such as  $\alpha$ 1-microglobulin can be used as a treatment or prophylaxis for pre-eclampsia. Therefore the study consists of two outcomes:

**Primary outcome:** fetal hemoglobin in maternal blood is increased with an increase of severity in pre-eclamptic patients.

**Secondary outcome:** fetal hemoglobin is a factor involved in the pathology of pre-eclampsia and antioxidant substances like  $\alpha$ 1-microglobulin can be used to counteract fetal hemoglobin and hence treat or prevent pre-eclampsia.